Literature DB >> 1427770

Molecular genotyping of N-acetylation polymorphism to predict phenotype.

M Mashimo1, T Suzuki, M Abe, T Deguchi.   

Abstract

N-acetylation polymorphism is one of the representative pharmacogenetic traits that underlie interindividual and interethnic differences in response to xenobiotics. To develop a practical genotyping method to predict acetylator phenotype, we studied the conditions for accurate phenotyping, and identified the phenotype in 51 Japanese. Then we performed Southern blot analysis of genomic DNA from these subjects using 32P-labeled cDNA for polymorphic N-acetyltransferase in the liver, and found that four N-acetyltransferase alleles generated six genotypes. The present genotyping method predicted the rapid, intermediate, and slow acetylators correctly in 48 of 51 overall subjects (96%) and in all of 4 slow acetylators.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1427770     DOI: 10.1007/bf00210758

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  14 in total

1.  Genetical and geographic studies on isoniazid inactivation.

Authors:  S SUNAHARA
Journal:  Science       Date:  1961-11-10       Impact factor: 47.728

Review 2.  Polymorphism in human N-acetyltransferase--the case of the missing allele.

Authors:  E Sime; D Hickman
Journal:  Trends Pharmacol Sci       Date:  1991-06       Impact factor: 14.819

Review 3.  N-acetyltransferase.

Authors:  D A Evans
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

4.  Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver.

Authors:  S Ohsako; T Deguchi
Journal:  J Biol Chem       Date:  1990-03-15       Impact factor: 5.157

5.  Isolation of genomic DNA.

Authors:  B G Herrmann; A M Frischauf
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

6.  High-performance liquid chromatographic analysis of isoniazid and acetylisoniazid in biological fluids.

Authors:  A Hutchings; R D Monie; B Spragg; P A Routledge
Journal:  J Chromatogr       Date:  1983-10-14

7.  Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases.

Authors:  T Ebisawa; T Deguchi
Journal:  Biochem Biophys Res Commun       Date:  1991-06-28       Impact factor: 3.575

8.  Molecular mechanism of slow acetylation of drugs and carcinogens in humans.

Authors:  M Blum; A Demierre; D M Grant; M Heim; U A Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

9.  Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression.

Authors:  M Blum; D M Grant; W McBride; M Heim; U A Meyer
Journal:  DNA Cell Biol       Date:  1990-04       Impact factor: 3.311

10.  A method to prevent the loss of isoniazid and acetylisoniazid in human plasma.

Authors:  A Hutchings; R D Monie; B Spragg; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

View more
  11 in total

1.  Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.

Authors:  I Cascorbi; N Drakoulis; J Brockmöller; A Maurer; K Sperling; I Roots
Journal:  Am J Hum Genet       Date:  1995-09       Impact factor: 11.025

2.  The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population.

Authors:  Bing Chen; Wei-Xia Zhang; Wei-Min Cai
Journal:  Eur J Clin Pharmacol       Date:  2006-03-29       Impact factor: 2.953

3.  Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals.

Authors:  Valery V Bakayev; Forozan Mohammadi; Moslem Bahadori; Mariam Sheikholslami; Arash Javeri; Mohammad R Masjedi; Ali A Velayati
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

4.  N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.

Authors:  Shunichi Kumagai; Fusao Komada; Tomoko Kita; Akio Morinobu; Shoichi Ozaki; Hiroshi Ishida; Hajime Sano; Tsukasa Matsubara; Katsuhiko Okumura
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

Review 5.  Acetylation as an indicator of risk.

Authors:  N P Lang
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

Review 6.  Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer.

Authors:  A Hirvonen
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

Review 7.  Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy - case report and literature review.

Authors:  Stefan Matei Constantinescu; Benoit Buysschaert; Vincent Haufroid; Franck Broly; Michel Jadoul; Johann Morelle
Journal:  BMC Nephrol       Date:  2017-09-04       Impact factor: 2.388

8.  Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients.

Authors:  A Toure; M Cabral; A Niang; C Diop; A Garat; L Humbert; M Fall; A Diouf; F Broly; M Lhermitte; D Allorge
Journal:  Toxicol Rep       Date:  2016-10-17

9.  NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.

Authors:  Junichi Azuma; Masako Ohno; Ryuji Kubota; Soichiro Yokota; Takayuki Nagai; Kazunari Tsuyuguchi; Yasuhisa Okuda; Tetsuya Takashima; Sayaka Kamimura; Yasushi Fujio; Ichiro Kawase
Journal:  Eur J Clin Pharmacol       Date:  2012-11-14       Impact factor: 2.953

10.  Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants.

Authors:  E Zielińska; W Niewiarowski; J Bodalski; G Rebowski; J Skretkowicz; K Mianowska; M Sekulska
Journal:  Pharm World Sci       Date:  1998-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.